Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05074355 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05074355 · ClinicalTrials.gov record · last posted 2026-07-06

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Name: Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms — clinical trial record (NCT05074355)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorUniversity Health Network, Toronto

Started2023-11-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2021-09-29; most recent amendment 2026-07-02. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-02-01

Status change Not Yet Recruiting→Recruitingv3

Trial Details

NCT Number	NCT05074355
Lead Sponsor	University Health Network, Toronto
Conditions	Myeloproliferative Neoplasm
Enrollment	40 participants
Start Date	2023-11-08
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-06